{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T12:22:41Z","timestamp":1780834961973,"version":"3.54.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tafenoquine is an 8-aminoquinoline anti-malarial drug recently approved as a single-dose (300\u00a0mg) therapy for <jats:italic>Plasmodium vivax<\/jats:italic> relapse prevention, when co-administered with 3-days of chloroquine or other blood schizonticide. Tafenoquine 200\u00a0mg weekly after a loading dose is also approved as travellers\u2019 prophylaxis. The development of tafenoquine has been conducted over many years, using various dosing regimens in diverse populations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This review brings together all the preclinical and clinical data concerning tafenoquine central nervous system safety. Data were assembled from published sources. The risk of neuropsychiatric adverse events (NPAEs) with single-dose tafenoquine (300\u00a0mg) in combination with chloroquine to achieve <jats:italic>P. vivax<\/jats:italic> relapse prevention is particularly examined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was no evidence of neurotoxicity with tafenoquine in preclinical animal models. In clinical studies in <jats:italic>P. vivax<\/jats:italic> relapse prevention, nervous system adverse events, mainly headache and dizziness, occurred in 11.4% (36\/317) of patients with tafenoquine (300\u00a0mg)\/chloroquine versus 10.2% (19\/187) with placebo\/chloroquine; and in 15.5% (75\/483) of patients with tafenoquine\/chloroquine versus 13.3% (35\/264) with primaquine (15\u00a0mg\/day for 14\u00a0days)\/chloroquine. Psychiatric adverse events, mainly insomnia, occurred in 3.8% (12\/317) of patients with tafenoquine\/chloroquine versus 2.7% (5\/187) with placebo\/chloroquine; and in 2.9% (14\/483) of patients with tafenoquine\/chloroquine versus 3.4% (9\/264) for primaquine\/chloroquine. There were no serious or severe NPAEs observed with tafenoquine (300\u00a0mg)\/chloroquine in these studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The risk:benefit of single-dose tafenoquine\/chloroquine in <jats:italic>P. vivax<\/jats:italic> relapse prevention is favourable in the presence of malaria, with a low risk of NPAEs, similar to that seen with chloroquine alone or primaquine\/chloroquine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-020-03184-x","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T02:02:44Z","timestamp":1584151364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review"],"prefix":"10.1186","volume":"19","author":[{"given":"Stephan","family":"Duparc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Chalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Toovey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,14]]},"reference":[{"key":"3184_CR1","doi-asserted-by":"publisher","first-page":"e0168780","DOI":"10.1371\/journal.pone.0168780","volume":"12","author":"SJ Lee","year":"2017","unstructured":"Lee SJ, Ter Kuile FO, Price RN, Luxemburger C, Nosten F. Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: a pooled analysis of 19,850 individual patients. PLoS ONE. 2017;12:e0168780.","journal-title":"PLoS ONE"},{"key":"3184_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4269\/ajtmh.16-0390","volume":"96","author":"AA Eick-Cost","year":"2017","unstructured":"Eick-Cost AA, Hu Z, Rohrbeck P, Clark LL. Neuropsychiatric outcomes after mefloquine exposure among US Military service members. Am J Trop Med Hyg. 2017;96:159\u201366.","journal-title":"Am J Trop Med Hyg"},{"key":"3184_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.tmaid.2014.10.021","volume":"13","author":"A Ringqvist","year":"2015","unstructured":"Ringqvist A, Bech P, Glenthoj B, Petersen E. Acute and long-term psychiatric side effects of mefloquine: a follow-up on Danish adverse event reports. Travel Med Infect Dis. 2015;13:80\u20138.","journal-title":"Travel Med Infect Dis"},{"key":"3184_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.tmaid.2008.12.004","volume":"7","author":"S Toovey","year":"2009","unstructured":"Toovey S. Mefloquine neurotoxicity: a literature review. Travel Med Infect Dis. 2009;7:2\u20136.","journal-title":"Travel Med Infect Dis"},{"key":"3184_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.12688\/wellcomeopenres.10658.1","volume":"2","author":"MA Bitta","year":"2017","unstructured":"Bitta MA, Kariuki SM, Mwita C, Gwer S, Mwai L, Newton C. Antimalarial drugs and the prevalence of mental and neurological manifestations: a systematic review and meta-analysis. Wellcome Open Res. 2017;2:13.","journal-title":"Wellcome Open Res"},{"key":"3184_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12936-015-0991-x","volume":"14","author":"GS Dow","year":"2015","unstructured":"Dow GS, Liu J, Lin G, Hetzell B, Thieling S, McCarthy WF, et al. Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries. Malar J. 2015;14:473.","journal-title":"Malar J"},{"key":"3184_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1128\/AAC.00354-09","volume":"54","author":"PE Nasveld","year":"2010","unstructured":"Nasveld PE, Edstein MD, Reid M, Brennan L, Harris IE, Kitchener SJ, et al. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother. 2010;54:792\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"3184_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.tmaid.2015.03.010","volume":"13","author":"P Schlagenhauf","year":"2015","unstructured":"Schlagenhauf P, Hatz C, Behrens R, Visser L, Funk M, Holzer B, et al. Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe. Travel Med Infect Dis. 2015;13:192\u20136.","journal-title":"Travel Med Infect Dis"},{"key":"3184_CR9","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(13)62568-4","volume":"383","author":"A Llanos-Cuentas","year":"2014","unstructured":"Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383:1049\u201358.","journal-title":"Lancet"},{"key":"3184_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1710775","volume":"380","author":"M Lacerda","year":"2019","unstructured":"Lacerda M, Llanos-Cuentas A, Krudsood S, Lon C, Saunders D, Mohammed R, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:215\u201328.","journal-title":"N Engl J Med"},{"key":"3184_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa1802537","volume":"380","author":"A Llanos-Cuentas","year":"2019","unstructured":"Llanos-Cuentas A, Lacerda M, Tinh Hien T, V\u00e9lez I, Namaik-larp C, Chu C, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:229\u201341.","journal-title":"N Engl J Med"},{"key":"3184_CR12","doi-asserted-by":"publisher","first-page":"e39645","DOI":"10.1371\/journal.pone.0039645","volume":"7","author":"JR Kim","year":"2012","unstructured":"Kim JR, Nandy A, Maji AK, Addy M, Dondorp AM, Day NP, et al. Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata. PLoS ONE. 2012;7:e39645.","journal-title":"PLoS ONE"},{"key":"3184_CR13","doi-asserted-by":"publisher","first-page":"e1002379","DOI":"10.1371\/journal.pmed.1002379","volume":"14","author":"NM Douglas","year":"2017","unstructured":"Douglas NM, Poespoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, et al. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study. PLoS Med. 2017;14:e1002379.","journal-title":"PLoS Med"},{"key":"3184_CR14","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1212\/WNL.0000000000002633","volume":"86","author":"CS Chui","year":"2016","unstructured":"Chui CS, Chan EW, Wong AY, Root A, Douglas IJ, Wong IC. Association between oral fluoroquinolones and seizures: a self-controlled case series study. Neurology. 2016;86:1708\u201315.","journal-title":"Neurology"},{"key":"3184_CR15","first-page":"220","volume":"66","author":"SH Bauquier","year":"2016","unstructured":"Bauquier SH, Jiang JL, Lai A, Cook MJ. Clonic seizures in GAERS rats after oral administration of enrofloxacin. Comp Med. 2016;66:220\u20134.","journal-title":"Comp Med"},{"key":"3184_CR16","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1212\/WNL.0000000000002023","volume":"85","author":"R Sutter","year":"2015","unstructured":"Sutter R, Ruegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: a systematic review. Neurology. 2015;85:1332\u201341.","journal-title":"Neurology"},{"key":"3184_CR17","first-page":"32","volume":"58","author":"AD Dayan","year":"1998","unstructured":"Dayan AD. Neurotoxicity and artemisinin compounds: do the observations in animals justify limitation of clinical use? Med Trop. 1998;58:32\u20137.","journal-title":"Med Trop"},{"key":"3184_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00204-007-0252-z","volume":"82","author":"RF Genovese","year":"2008","unstructured":"Genovese RF, Newman DB. Understanding artemisinin-induced brainstem neurotoxicity. Arch Toxicol. 2008;82:379\u201385.","journal-title":"Arch Toxicol"},{"key":"3184_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4269\/ajtmh.1997.56.7","volume":"56","author":"S Kamchonwongpaisan","year":"1997","unstructured":"Kamchonwongpaisan S, McKeever P, Hossler P, Ziffer H, Meshnick SR. Artemisinin neurotoxicity: neuropathology in rats and mechanistic studies in vitro. Am J Trop Med Hyg. 1997;56:7\u201312.","journal-title":"Am J Trop Med Hyg"},{"key":"3184_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4269\/ajtmh.1998.59.519","volume":"59","author":"A Nontprasert","year":"1998","unstructured":"Nontprasert A, Nosten-Bertrand M, Pukrittayakamee S, Vanijanonta S, Angus BJ, White NJ. Assessment of the neurotoxicity of parenteral artemisinin derivatives in mice. Am J Trop Med Hyg. 1998;59:519\u201322.","journal-title":"Am J Trop Med Hyg"},{"key":"3184_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4269\/ajtmh.2000.62.409","volume":"62","author":"A Nontprasert","year":"2000","unstructured":"Nontprasert A, Pukrittayakamee S, Nosten-Bertrand M, Vanijanonta S, White NJ. Studies of the neurotoxicity of oral artemisinin derivatives in mice. Am J Trop Med Hyg. 2000;62:409\u201312.","journal-title":"Am J Trop Med Hyg"},{"key":"3184_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tox.2010.09.005","volume":"279","author":"Q Li","year":"2011","unstructured":"Li Q, Hickman M. Toxicokinetic and toxicodynamic (TK\/TD) evaluation to determine and predict the neurotoxicity of artemisinins. Toxicology. 2011;279:1\u20139.","journal-title":"Toxicology"},{"key":"3184_CR23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.4269\/ajtmh.2002.66.516","volume":"66","author":"QG Li","year":"2002","unstructured":"Li QG, Mog SR, Si YZ, Kyle DE, Gettayacamin M, Milhous WK. Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents. Am J Trop Med Hyg. 2002;66:516\u201325.","journal-title":"Am J Trop Med Hyg"},{"key":"3184_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3109\/10408441003610571","volume":"40","author":"T Efferth","year":"2010","unstructured":"Efferth T, Kaina B. Toxicity of the antimalarial artemisinin and its dervatives. Crit Rev Toxicol. 2010;40:405\u201321.","journal-title":"Crit Rev Toxicol"},{"key":"3184_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.toxlet.2003.12.009","volume":"147","author":"T Gordi","year":"2004","unstructured":"Gordi T, Lepist EI. Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett. 2004;147:99\u2013107.","journal-title":"Toxicol Lett"},{"key":"3184_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12936-015-0682-7","volume":"14","author":"AB Tiono","year":"2015","unstructured":"Tiono AB, Tinto H, Alao MJ, Meremikwu M, Tshefu A, Ogutu B, et al. Increased systemic exposures of artemether and dihydroartemisinin in infants under 5\u00a0kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem(R)). Malar J. 2015;14:157.","journal-title":"Malar J"},{"key":"3184_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1128\/AAC.47.1.368-370.2003","volume":"47","author":"TM Davis","year":"2003","unstructured":"Davis TM, Binh TQ, Ilett KF, Batty KT, Phuong HL, Chiswell GM, et al. Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria. Antimicrob Agents Chemother. 2003;47:368\u201370.","journal-title":"Antimicrob Agents Chemother"},{"key":"3184_CR28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/14740338.2016.1175428","volume":"15","author":"B Grabias","year":"2016","unstructured":"Grabias B, Kumar S. Adverse neuropsychiatric effects of antimalarial drugs. Expert Opin Drug Saf. 2016;15:903\u201310.","journal-title":"Expert Opin Drug Saf"},{"key":"3184_CR29","unstructured":"Centers for Disease Control and Prevention. Malaria: disease. CDC. 2018. https:\/\/www.cdc.gov\/malaria\/about\/disease.html. Accessed 24 Feb 2020."},{"key":"3184_CR30","doi-asserted-by":"publisher","first-page":"e2012026","DOI":"10.4084\/mjhid.2012.026","volume":"4","author":"A Bartoloni","year":"2012","unstructured":"Bartoloni A, Zammarchi L. Clinical aspects of uncomplicated and severe malaria. Mediterr J Hematol Infect Dis. 2012;4:e2012026.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"3184_CR31","doi-asserted-by":"publisher","first-page":"e20161965","DOI":"10.1542\/peds.2016-1965","volume":"138","author":"JM Ssenkusu","year":"2016","unstructured":"Ssenkusu JM, Hodges JS, Opoka RO, Idro R, Shapiro E, John CC, et al. Long-term behavioral problems in children with severe malaria. Pediatrics. 2016;138:e20161965.","journal-title":"Pediatrics"},{"key":"3184_CR32","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1542\/peds.2006-2027","volume":"119","author":"MJ Boivin","year":"2007","unstructured":"Boivin MJ, Bangirana P, Byarugaba J, Opoka RO, Idro R, Jurek AM, et al. Cognitive impairment after cerebral malaria in children: a prospective study. Pediatrics. 2007;119:e360\u20136.","journal-title":"Pediatrics"},{"key":"3184_CR33","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1542\/peds.2007-3709","volume":"122","author":"CC John","year":"2008","unstructured":"John CC, Bangirana P, Byarugaba J, Opoka RO, Idro R, Jurek AM, et al. Cerebral malaria in children is associated with long-term cognitive impairment. Pediatrics. 2008;122:e92\u20139.","journal-title":"Pediatrics"},{"key":"3184_CR34","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/1475-2875-9-366","volume":"9","author":"SD Fernando","year":"2010","unstructured":"Fernando SD, Rodrigo C, Rajapakse S. The \u2018hidden\u2019 burden of malaria: cognitive impairment following infection. Malar J. 2010;9:366.","journal-title":"Malar J"},{"key":"3184_CR35","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1586\/eri.10.117","volume":"8","author":"GA Zimmerman","year":"2010","unstructured":"Zimmerman GA, Castro-Faria-Neto H. Persistent cognitive impairment after cerebral malaria: models, mechanisms and adjunctive therapies. Expert Rev Anti Infect Ther. 2010;8:1209\u201312.","journal-title":"Expert Rev Anti Infect Ther."},{"key":"3184_CR36","doi-asserted-by":"publisher","first-page":"e55653","DOI":"10.1371\/journal.pone.0055653","volume":"8","author":"P Bangirana","year":"2013","unstructured":"Bangirana P, Menk J, John CC, Boivin MJ, Hodges JS. The association between cognition and academic performance in Ugandan children surviving malaria with neurological involvement. PLoS ONE. 2013;8:e55653.","journal-title":"PLoS ONE"},{"key":"3184_CR37","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/1475-2875-10-334","volume":"10","author":"P Bangirana","year":"2011","unstructured":"Bangirana P, Musisi S, Boivin MJ, Ehnvall A, John CC, Bergemann TL, et al. Malaria with neurological involvement in Ugandan children: effect on cognitive ability, academic achievement and behaviour. Malar J. 2011;10:334.","journal-title":"Malar J"},{"key":"3184_CR38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0035-9203(99)90368-1","volume":"93","author":"PA Holding","year":"1999","unstructured":"Holding PA, Stevenson J, Peshu N, Marsh K. Cognitive sequelae of severe malaria with impaired consciousness. Trans R Soc Trop Med Hyg. 1999;93:529\u201334.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3184_CR39","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12936-016-1233-6","volume":"15","author":"R Idro","year":"2016","unstructured":"Idro R, Kakooza-Mwesige A, Asea B, Ssebyala K, Bangirana P, Opoka RO, et al. Cerebral malaria is associated with long-term mental health disorders: a cross sectional survey of a long-term cohort. Malar J. 2016;15:184.","journal-title":"Malar J"},{"key":"3184_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0379-0738(94)90376-X","volume":"68","author":"R Jones","year":"1994","unstructured":"Jones R, Kunsman G, Levine B, Smith M, Stahl C. Mefloquine distribution in postmortem cases. Forensic Sci Int. 1994;68:29\u201332.","journal-title":"Forensic Sci Int"},{"key":"3184_CR41","first-page":"58","volume":"37","author":"YT Pham","year":"1999","unstructured":"Pham YT, Nosten F, Farinotti R, White NJ, Gimenez F. Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol Ther. 1999;37:58\u201361.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3184_CR42","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1128\/AAC.50.3.1045-1053.2006","volume":"50","author":"G Dow","year":"2006","unstructured":"Dow G, Bauman R, Caridha D, Cabezas M, Du F, Gomez-Lobo R, et al. Mefloquine induces dose-related neurological effects in a rat model. Antimicrob Agents Chemother. 2006;50:1045\u201353.","journal-title":"Antimicrob Agents Chemother"},{"key":"3184_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1475-2875-2-14","volume":"2","author":"GS Dow","year":"2003","unstructured":"Dow GS, Hudson TH, Vahey M, Koenig ML. The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro. Malar J. 2003;2:14.","journal-title":"Malar J"},{"key":"3184_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1742-7843.2008.00256.x","volume":"103","author":"S Toovey","year":"2008","unstructured":"Toovey S, Bustamante LY, Uhlemann AC, East JM, Krishna S. Effect of artemisinins and amino alcohol partner antimalarials on mammalian sarcoendoplasmic reticulum calcium adenosine triphosphatase activity. Basic Clin Pharmacol Toxicol. 2008;103:209\u201313.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3184_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.envint.2015.05.009","volume":"82","author":"JF Viel","year":"2015","unstructured":"Viel JF, Warembourg C, Le Maner-Idrissi G, Lacroix A, Limon G, Rouget F, et al. Pyrethroid insecticide exposure and cognitive developmental disabilities in children: the PELAGIE mother-child cohort. Environ Int. 2015;82:69\u201375.","journal-title":"Environ Int"},{"key":"3184_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12640-015-9572-6","volume":"29","author":"A Wnuk","year":"2016","unstructured":"Wnuk A, Rzemieniec J, Litwa E, Lason W, Krzeptowski W, Wojtowicz AK, et al. The crucial involvement of retinoid X receptors in DDE neurotoxicity. Neurotox Res. 2016;29:155\u201372.","journal-title":"Neurotox Res"},{"key":"3184_CR47","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00204-011-0726-x","volume":"86","author":"DM Soderlund","year":"2012","unstructured":"Soderlund DM. Molecular mechanisms of pyrethroid insecticide neurotoxicity: recent advances. Arch Toxicol. 2012;86:165\u201381.","journal-title":"Arch Toxicol"},{"key":"3184_CR48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ajp.2017.10.029","volume":"38","author":"S Yatham","year":"2017","unstructured":"Yatham S, Sivathasan S, Yoon R, da Silva TL, Ravindran AV. Depression, anxiety, and post-traumatic stress disorder among youth in low and middle income countries: a review of prevalence and treatment interventions. Asian J Psychiatr. 2017;38:78\u201391.","journal-title":"Asian J Psychiatr"},{"key":"3184_CR49","first-page":"51","volume":"46","author":"C Gomez-Restrepo","year":"2018","unstructured":"Gomez-Restrepo C, Cruz-Ramirez V, Medina-Rico M, Rincon CJ. Mental health in displaced children by armed conflict\u2014National Mental Health Survey Colombia 2015. Actas Esp Psiquiatr. 2018;46:51\u20137.","journal-title":"Actas Esp Psiquiatr"},{"key":"3184_CR50","unstructured":"World Bank. Malaria. World Bank. 2015. http:\/\/www.worldbank.org\/en\/topic\/health\/brief\/malaria. Accessed 24 Feb 2020."},{"key":"3184_CR51","first-page":"839743","volume":"2011","author":"R Salgado-Delgado","year":"2011","unstructured":"Salgado-Delgado R, Tapia Osorio A, Saderi N, Escobar C. Disruption of circadian rhythms: a crucial factor in the etiology of depression. Depress Res Treat. 2011;2011:839743.","journal-title":"Depress Res Treat"},{"key":"3184_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/10937404.2018.1427914","volume":"21","author":"JN Kim","year":"2018","unstructured":"Kim JN, Lee BM. Risk management of free radicals involved in air travel syndromes by antioxidants. J Toxicol Environ Health B Crit Rev. 2018;21:47\u201360.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"3184_CR53","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/JOM.0000000000001262","volume":"60","author":"AG Rundle","year":"2018","unstructured":"Rundle AG, Revenson TA, Friedman M. Business travel and behavioral and mental health. J Occup Environ Med. 2018;60:612\u20136.","journal-title":"J Occup Environ Med"},{"key":"3184_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.tmaid.2017.05.008","volume":"17","author":"A Novitt-Moreno","year":"2017","unstructured":"Novitt-Moreno A, Ransom J, Dow G, Smith B, Read LT, Toovey S. Tafenoquine for malaria prophylaxis in adults: an integrated safety analysis. Travel Med Infect Dis. 2017;17:19\u201327.","journal-title":"Travel Med Infect Dis"},{"key":"3184_CR55","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/mpr.166","volume":"13","author":"RC Kessler","year":"2004","unstructured":"Kessler RC, Merikangas KR. The National Comorbidity Survey Replication (NCS-R): background and aims. Int J Methods Psychiatr Res. 2004;13:60\u20138.","journal-title":"Int J Methods Psychiatr Res"},{"key":"3184_CR56","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1001\/jamapsychiatry.2014.28","volume":"71","author":"RC Kessler","year":"2014","unstructured":"Kessler RC, Heeringa SG, Stein MB, Colpe LJ, Fullerton CS, Hwang I, et al. Thirty-day prevalence of DSM-IV mental disorders among nondeployed soldiers in the US Army: results from the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). JAMA Psychiatry. 2014;71:504\u201313.","journal-title":"JAMA Psychiatry"},{"key":"3184_CR57","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamapsychiatry.2013.4417","volume":"71","author":"M Schoenbaum","year":"2014","unstructured":"Schoenbaum M, Kessler RC, Gilman SE, Colpe LJ, Heeringa SG, Stein MB, et al. Predictors of suicide and accident death in the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS): results from the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). JAMA Psychiatry. 2014;71:493\u2013503.","journal-title":"JAMA Psychiatry"},{"key":"3184_CR58","unstructured":"McFarlane A, Hodson S, N VH, C D. Mental health in the Australian Defence Force: 2010 ADF mental health prevalence and wellbeing study report. Department of Defence. 2011. http:\/\/www.defence.gov.au\/health\/dmh\/docs\/mhpwsreport-fullreport.pdf. Accessed 24 Feb 2020."},{"key":"3184_CR59","doi-asserted-by":"publisher","first-page":"46S","DOI":"10.1177\/0706743716628856","volume":"61","author":"C Rusu","year":"2016","unstructured":"Rusu C, Zamorski MA, Boulos D, Garber BG. Prevalence comparison of past-year mental disorders and suicidal behaviours in the Canadian Armed Forces and the Canadian general population. Can J Psychiatry. 2016;61:46S\u201355S.","journal-title":"Can J Psychiatry"},{"key":"3184_CR60","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1017\/S0033291714002980","volume":"45","author":"L Goodwin","year":"2015","unstructured":"Goodwin L, Wessely S, Hotopf M, Jones M, Greenberg N, Rona RJ, et al. Are common mental disorders more prevalent in the UK serving military compared to the general working population? Psychol Med. 2015;45:1881\u201391.","journal-title":"Psychol Med"},{"key":"3184_CR61","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/jamapsychiatry.2014.30","volume":"71","author":"MK Nock","year":"2014","unstructured":"Nock MK, Stein MB, Heeringa SG, Ursano RJ, Colpe LJ, Fullerton CS, et al. Prevalence and correlates of suicidal behavior among soldiers: results from the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). JAMA Psychiatry. 2014;71:514\u201322.","journal-title":"JAMA Psychiatry"},{"key":"3184_CR62","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1001\/jamapsychiatry.2014.24","volume":"71","author":"MJ Friedman","year":"2014","unstructured":"Friedman MJ. Suicide risk among soldiers: early findings from Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). JAMA Psychiatry. 2014;71:487\u20139.","journal-title":"JAMA Psychiatry"},{"key":"3184_CR63","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1192\/bjp.bp.111.097527","volume":"201","author":"K Mulligan","year":"2012","unstructured":"Mulligan K, Jones N, Davies M, McAllister P, Fear NT, Wessely S, et al. Effects of home on the mental health of British forces serving in Iraq and Afghanistan. Br J Psychiatry. 2012;201:193\u20138.","journal-title":"Br J Psychiatry"},{"key":"3184_CR64","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1017\/S204579601600024X","volume":"26","author":"S Trautmann","year":"2017","unstructured":"Trautmann S, Goodwin L, Hofler M, Jacobi F, Strehle J, Zimmermann P, et al. Prevalence and severity of mental disorders in military personnel: a standardised comparison with civilians. Epidemiol Psychiatr Sci. 2017;26:199\u2013208.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"3184_CR65","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.psychres.2017.09.046","volume":"262","author":"RJ Ursano","year":"2018","unstructured":"Ursano RJ, Stein MB, Herberman Mash HB, Naifeh JA, Fullerton CS, Zaslavsky AM, et al. Documented family violence and risk of suicide attempt among US Army soldiers. Psychiatry Res. 2018;262:575\u201382.","journal-title":"Psychiatry Res"},{"key":"3184_CR66","unstructured":"Ministry of Defence. UK Armed Forces mental health: annual summary & trends over time, 2007\/08\u20132016\/17. MOD. 2017. www.gov.uk\/government\/statistics\/mental-health-in-the-uk-armed-forces-background-quality-report. Accessed 24 Feb 2020."},{"key":"3184_CR67","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/sltb.12303","volume":"47","author":"HM Kim","year":"2017","unstructured":"Kim HM, Levine DS, Pfeiffer PN, Blow AJ, Marchiondo C, Walters H, et al. Postdeployment suicide risk increases over a 6-month period: predictors of increased risk among midwestern Army National Guard soldiers. Suicide Life Threat Behav. 2017;47:421\u201335.","journal-title":"Suicide Life Threat Behav"},{"key":"3184_CR68","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1521\/pdps.2014.42.3.459","volume":"42","author":"SG Lazar","year":"2014","unstructured":"Lazar SG. The mental health needs of military service members and veterans. Psychodyn Psychiatry. 2014;42:459\u201378.","journal-title":"Psychodyn Psychiatry"},{"key":"3184_CR69","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1177\/070674371405900903","volume":"59","author":"LA Hines","year":"2014","unstructured":"Hines LA, Sundin J, Rona RJ, Wessely S, Fear NT. Posttraumatic stress disorder post Iraq and Afghanistan: prevalence among military subgroups. Can J Psychiatry. 2014;59:468\u201379.","journal-title":"Can J Psychiatry"},{"key":"3184_CR70","unstructured":"Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems and barriers to care. US Army Med Dep J. 2008;7\u201317."},{"key":"3184_CR71","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/archpsyc.64.7.843","volume":"64","author":"J Sareen","year":"2007","unstructured":"Sareen J, Cox BJ, Afifi TO, Stein MB, Belik SL, Meadows G, et al. Combat and peacekeeping operations in relation to prevalence of mental disorders and perceived need for mental health care: findings from a large representative sample of military personnel. Arch Gen Psychiatry. 2007;64:843\u201352.","journal-title":"Arch Gen Psychiatry"},{"key":"3184_CR72","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/jrnms-100-232","volume":"100","author":"S Adshead","year":"2014","unstructured":"Adshead S. The adverse effects of mefloquine in deployed military personnel. J R Nav Med Serv. 2014;100:232\u20137.","journal-title":"J R Nav Med Serv"},{"key":"3184_CR73","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1128\/AAC.24.5.615","volume":"24","author":"LH Schmidt","year":"1983","unstructured":"Schmidt LH. Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in Rhesus monkeys. Antimicrob Agents Chemother. 1983;24:615\u201352.","journal-title":"Antimicrob Agents Chemother"},{"key":"3184_CR74","unstructured":"GlaxoSmithKline. Krintafel (tafenoquine succinate tablets): FDA Advisory Committee Briefing Document GSK. 2018. https:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/anti-infectivedrugsadvisorycommittee\/ucm612875.pdf. Accessed 24 Feb 2020."},{"key":"3184_CR75","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.tmaid.2017.05.006","volume":"17","author":"GS Dow","year":"2017","unstructured":"Dow GS, Brown T, Reid M, Smith B, Toovey S. Tafenoquine is not neurotoxic following supertherapeutic dosing in rats. Travel Med Infect Dis. 2017;17:28\u201334.","journal-title":"Travel Med Infect Dis"},{"key":"3184_CR76","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1475-2875-10-212","volume":"10","author":"GS Dow","year":"2011","unstructured":"Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, et al. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). Malar J. 2011;10:212.","journal-title":"Malar J"},{"key":"3184_CR77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0001-706X(02)00289-9","volume":"86","author":"SK Puri","year":"2003","unstructured":"Puri SK, Dutta GP. Blood schizontocidal activity of WR 238605 (tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in Rhesus monkeys. Acta Trop. 2003;86:35\u201340.","journal-title":"Acta Trop"},{"key":"3184_CR78","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1645\/13-480.1","volume":"100","author":"C DiTusa","year":"2014","unstructured":"DiTusa C, Kozar MP, Pybus B, Sousa J, Berman J, Gettayacamin M, et al. Causal prophylactic efficacy of primaquine, tafenoquine, and atovaquone-proguanil against Plasmodium cynomolgi in a rhesus monkey model. J Parasitol. 2014;100:671\u20133.","journal-title":"J Parasitol"},{"key":"3184_CR79","unstructured":"Sixty Degrees Pharmaceuticals. ARAKODA\u2122 (tafenoquine succinate) tablets for the prevention of malaria in adults: NDA 210607; briefing document for the Antimicrobial Drugs Advisory Committee. Sixty Degrees Pharmaceuticals. 2018. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM614202.pdf. Accessed 24 Feb 2020."},{"key":"3184_CR80","doi-asserted-by":"publisher","first-page":"e0187376","DOI":"10.1371\/journal.pone.0187376","volume":"12","author":"MM Fukuda","year":"2017","unstructured":"Fukuda MM, Krudsood S, Mohamed K, Green JA, Warrasak S, Noedl H, et al. A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria. PLoS ONE. 2017;12:e0187376.","journal-title":"PLoS ONE"},{"key":"3184_CR81","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1086\/424508","volume":"39","author":"DS Walsh","year":"2004","unstructured":"Walsh DS, Wilairatana P, Tang DB, Heppner DG Jr, Brewer TG, Krudsood S, et al. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis. 2004;39:1095\u2013103.","journal-title":"Clin Infect Dis"},{"key":"3184_CR82","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00005072-195107000-00001","volume":"10","author":"IG Schmidt","year":"1951","unstructured":"Schmidt IG, Schmidt LH. Neurotoxicity of the 8-aminoquinolines. III. The effects of pentaquine, isopentaquine, primaquine, and pamaquine on the central nervous system of the Rhesus monkey. J Neuropathol Exp Neurol. 1951;10:231\u201356.","journal-title":"J Neuropathol Exp Neurol"},{"key":"3184_CR83","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s12936-018-2555-3","volume":"17","author":"J Berman","year":"2018","unstructured":"Berman J, Brown T, Dow G, Toovey S. Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines. Malar J. 2018;17:407.","journal-title":"Malar J"},{"key":"3184_CR84","unstructured":"Sixty Degrees Pharmaceuticals. ARAKODA\u2122 (tafenoquine) tablets, for oral use; prescribing information. Sixty Degrees Pharmaceuticals. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210607lbl.pdf. Accessed 24 Feb 2020."},{"key":"3184_CR85","unstructured":"GlaxoSmithKline. KRINTAFEL (tafenoquine) tablets, for oral use; prescribing information. GlaxoSmithKline. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210795s000lbl.pdf. Accessed 24 Feb 2020."},{"key":"3184_CR86","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1471-244X-12-88","volume":"12","author":"M Waller","year":"2012","unstructured":"Waller M, Treloar SA, Sim MR, McFarlane AC, McGuire AC, Bleier J, et al. Traumatic events, other operational stressors and physical and mental health reported by Australian Defence Force personnel following peacekeeping and war-like deployments. BMC Psychiatry. 2012;12:88.","journal-title":"BMC Psychiatry"},{"key":"3184_CR87","doi-asserted-by":"publisher","first-page":"702","DOI":"10.4269\/ajtmh.16-0779","volume":"97","author":"R Rueangweerayut","year":"2017","unstructured":"Rueangweerayut R, Bancone G, Harrell EJ, Beelen AP, Kongpatanakul S, Mohrle JJ, et al. Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol variant) versus G6PD-normal volunteers. Am J Trop Med Hyg. 2017;97:702\u201311.","journal-title":"Am J Trop Med Hyg"},{"key":"3184_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004389.pub3","author":"GN Galappaththy","year":"2013","unstructured":"Galappaththy GN, Tharyan P, Kirubakaran R. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. Cochrane Database Syst Rev. 2013. https:\/\/doi.org\/10.1002\/14651858.CD004389.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"3184_CR89","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1086\/324081","volume":"33","author":"GD Shanks","year":"2001","unstructured":"Shanks GD, Oloo AJ, Aleman GM, Ohrt C, Klotz FW, Braitman D, et al. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis. 2001;33:1968\u201374.","journal-title":"Clin Infect Dis"},{"key":"3184_CR90","doi-asserted-by":"publisher","first-page":"645","DOI":"10.4269\/ajtmh.1998.58.645","volume":"58","author":"RP Brueckner","year":"1998","unstructured":"Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg. 1998;58:645\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"3184_CR91","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/jcph.302","volume":"54","author":"JA Green","year":"2014","unstructured":"Green JA, Patel AK, Patel BR, Hussaini A, Harrell EJ, McDonald MJ, et al. Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects. J Clin Pharmacol. 2014;54:995\u20131005.","journal-title":"J Clin Pharmacol"},{"key":"3184_CR92","doi-asserted-by":"publisher","first-page":"356","DOI":"10.4269\/ajtmh.2009.81.356","volume":"81","author":"KJ Leary","year":"2009","unstructured":"Leary KJ, Riel MA, Roy MJ, Cantilena LR, Bi D, Brater DC, et al. A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200\u00a0mg weekly versus placebo for 6\u00a0months in healthy volunteers. Am J Trop Med Hyg. 2009;81:356\u201362.","journal-title":"Am J Trop Med Hyg"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03184-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12936-020-03184-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03184-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T00:06:38Z","timestamp":1615680398000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-020-03184-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,14]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3184"],"URL":"https:\/\/doi.org\/10.1186\/s12936-020-03184-x","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,14]]},"assertion":[{"value":"25 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Stephan Duparc and Stephan Chalon are employees of Medicines for Malaria Venture. Scott Miller is an employee of the Bill and Melinda Gates Foundation. Scott Miller is a retired U. S. Army officer, and his views are his own and not those of the U.S. Army or the U.S. Department of Defense. Naomi Richardson received funding from Medicines for Malaria Venture in regard to this article and has been previously employed as an external communications consultant by GlaxoSmithKline and Medicines for Malaria Venture. Stephen Toovey has been employed as a consultant to Medicines for Malaria Venture in regard to this article and to GlaxoSmithKline and 60P Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}